Save Product
Product Details
Source
Chimeric Monoclonal Anti-MMAF specific Antibody, Rabbit IgG (1M1E12) is recombinantly expressed in HEK293. It consists of rabbit variable regions genetically fused to rabbit IgG constant domains.
Antibody Type
Recombinant Monoclonal
Clone
1M1E12
Isotype
Rabbit IgG, Kappa
Host Species
Rabbit
Immunogen
MMAF-BSA
Specificity
Specifically recognizes MMAF and does not recognize MMAE.
Application
ApplicationRecommended Use / PerformanceELISA0.2-2 μg/mLPurification
Protein A purified.
Concentration
Please refer to the Certificate of Analysis (CoA).
Form
Lyophilized
Formulation
Lyophilized from a 0.22 μm-filtered solution in PBS (pH 7.4), with trehalose as protectant.
Please contact us for customized product forms or formulations.
Reconstitution
Please refer to the Certificate of Analysis (CoA) for specific instructions.
Shipping
Lyophilized product is shipped at ambient temperature.
Storage
For long term storage, the product should be stored in a lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
- -20°C to -70°C for 12 months in lyophilized state;
- -70°C for 3 months under sterile conditions after reconstitution.
Notices
Product Specific Notices: For research use only.
ACRO Quality Management System
Customers Also Viewed
Performance Data
Bioactivity-ELISA
Immobilized IgG1-MMAF at 0.2 μg/mL (100 μL/well) can bind Monoclonal Anti-MMAF specific Antibody, Rabbit IgG (1M1E12) (Cat. No. MMF-MY2214) with a linear range of 0.06-2 ng/mL (QC tested).
Protocol
Serial dilutions of MMAF were added into Monoclonal Anti-MMAF specific Antibody, Rabbit IgG (1M1E12) (Cat. No. MMF-MY2214): IgG1-MMAF binding reactions. The half maximal inhibitory concentration (IC50) is 0.1106 μg/mL (Routinely tested).
Protocol
Cross Verification
ELISA binding of Monoclonal Anti-MMAF specific Antibody, Rabbit IgG (1M1E12) (Cat. No. MMF-MY2214) with Doxorubicin-ADC, Disitamab Vedotin (RC48), IgG1-MMAF, Trastuzumab Deruxtecan, Sacituzumab Govitecan and Trastuzumab-DM1 conju-gated antibody respectively.
The coating antibody was Monoclonal Anti-MMAF specific Antibody, Rabbit IgG (1M1E12) (Cat. No. MMF-MY2214), used at 1 μg/mL concentration. The primary an-tibody were different payload conjugated antibodies, including Doxorubicin-ADC, Disitamab Vedotin (RC48), IgG1-MMAF, Trastuzumab Deruxtecan, Sacituzumab Govitecan and Trastuzumab-DM1 conjugated antibodies used at 0.25 μg/mL con-centration. The secondary antibody was HRP conjugated Anti-Human-IgG-Fc Anti-body (6F11C8), mAb (Acro, Cat. No. IGG-LY69) used at 1:10000 concentration.
Monoclonal Anti-MMAF specific Antibody, Rabbit IgG (1M1E12) (Cat. No. MMF-MY2214) is specific to IgG1-MMAF and has no cross-reactivity with Doxorubi-cin-ADC, Disitamab Vedotin (RC48), Trastuzumab Deruxtecan, Sacituzumab Govitecan and Trastuzumab-DM1 (Routinely tested).
Customer Reviews Writing Reviews
FAQ
- product
Can lyophilized proteins remain stable during room-temperature shipping or temporary room-temperature exposure?
In general, lyophilized proteins remain stable during room-temperature shipping or temporary exposure to room-temperature conditions.
Many ACROBiosystems recombinant proteins are supplied in lyophilized (freeze-dried) form. The lyophilization process effectively removes moisture from the product, helping reduce degradation-related reactions and improve protein stability during transportation and storage.
To evaluate the stability of lyophilized proteins under normal temperature conditions, ACROBiosystems conducted a stability study on 11 representative lyophilized protein products at 37°C. The study demonstrated that these proteins maintained good quality stability after storage at 37°C for approximately 20 days. Based on these validation results, temporary room-temperature exposure during shipping or handling is generally not expected to have a significant impact on product quality or downstream application performance.
To ensure optimal long-term stability, products should be stored according to the storage conditions specified in the product Certificate of Analysis (COA) upon receipt.
Supporting Document
Background
Recent Advances
Contact Us
[North America]: +1 800-810-0816
[Switzerland]: +41 800 040 012
[Asia & Pacific]: +86 400-682-2521
Drug Candidate Licensing
